FDA NDA · NDA021175
ATNAA ATROPINE AND PRALIDOXIME CHLORIDE AUTO-INJECTOR
atropine and pralidoxime chloride
Sponsor: US ARMY
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
NDA021175
TYPE
NDA
ORIGINAL APPROVAL
2002-01-17
LATEST ACTION
2026-10-10
ROUTE
INTRAMUSCULAR
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued
Products
ATNAADiscontinued
ATROPINE 2.1MG/0.7ML, PRALIDOXIME CHLORIDE 600MG/2ML · INJECTABLE · INTRAMUSCULAR
Approval history
2026-10-10Labeling · Supplement 56 · standardAP
2016-11-03Manufacturing (CMC) · Supplement 32 · standardAP
2016-05-27Manufacturing (CMC) · Supplement 31 · priorityAP
2016-04-25Manufacturing (CMC) · Supplement 30 · priorityAP
2016-03-02Manufacturing (CMC) · Supplement 27 · priorityAP
2015-12-11Manufacturing (CMC) · Supplement 29 · priorityAP
2015-09-22Manufacturing (CMC) · Supplement 28 · priorityAP
2015-02-03Manufacturing (CMC) · Supplement 26 · priorityAP
2015-01-20Manufacturing (CMC) · Supplement 25 · priorityAP
2014-05-15Manufacturing (CMC) · Supplement 24 · priorityAP
2002-09-10Manufacturing (CMC) · Supplement 1 · priorityAP
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →